BR112022016573A2 - Inibidores de setd2 e métodos e usos relacionados, incluindo terapias de combinação - Google Patents
Inibidores de setd2 e métodos e usos relacionados, incluindo terapias de combinaçãoInfo
- Publication number
- BR112022016573A2 BR112022016573A2 BR112022016573A BR112022016573A BR112022016573A2 BR 112022016573 A2 BR112022016573 A2 BR 112022016573A2 BR 112022016573 A BR112022016573 A BR 112022016573A BR 112022016573 A BR112022016573 A BR 112022016573A BR 112022016573 A2 BR112022016573 A2 BR 112022016573A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- setd2
- related methods
- combination therapies
- including combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978692P | 2020-02-19 | 2020-02-19 | |
| PCT/US2021/018863 WO2021168313A1 (en) | 2020-02-19 | 2021-02-19 | Setd2 inhibitors and related methods and uses, including combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016573A2 true BR112022016573A2 (pt) | 2022-11-08 |
Family
ID=77391740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016573A BR112022016573A2 (pt) | 2020-02-19 | 2021-02-19 | Inibidores de setd2 e métodos e usos relacionados, incluindo terapias de combinação |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230133671A1 (https=) |
| EP (1) | EP4107157A4 (https=) |
| JP (1) | JP2023514280A (https=) |
| KR (1) | KR20220143116A (https=) |
| CN (2) | CN121695288A (https=) |
| AU (1) | AU2021224855A1 (https=) |
| BR (1) | BR112022016573A2 (https=) |
| CA (1) | CA3168069A1 (https=) |
| IL (1) | IL295654A (https=) |
| MX (1) | MX2022010171A (https=) |
| WO (1) | WO2021168313A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020530844A (ja) | 2017-08-14 | 2020-10-29 | エピザイム，インコーポレイティド | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| CN111093660A (zh) * | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| CN112585119A (zh) | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| US20240299352A1 (en) * | 2021-06-09 | 2024-09-12 | Epizyme, Inc. | Combination therapies with setd2 inhibitors |
| JP2024539726A (ja) * | 2021-11-01 | 2024-10-29 | エピザイム，インコーポレイティド | Ｎ－（（１ｒ，３ｓ）－３－（４－アセチルピペラジン－１－イル）シクロヘキシル）－４－フルオロ－７－メチル－１ｈ－インドール－２－カルボキサミドの結晶形態 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595766A (en) * | 1984-10-26 | 1986-06-17 | Ciba-Geigy Corporation | Process for the preparation of an indoline carboxylic acid |
| US20100035862A1 (en) * | 2008-06-25 | 2010-02-11 | Abbott Laboratories | Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
| NZ725860A (en) * | 2014-04-04 | 2019-08-30 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| WO2016040505A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Smyd inhibitors |
| CN112585119A (zh) * | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| SG11202105325QA (en) * | 2018-11-30 | 2021-06-29 | Epizyme Inc | Methods of treating whsc1-overexpressing cancers by inhibiting setd2 |
-
2021
- 2021-02-19 WO PCT/US2021/018863 patent/WO2021168313A1/en not_active Ceased
- 2021-02-19 BR BR112022016573A patent/BR112022016573A2/pt unknown
- 2021-02-19 US US17/904,570 patent/US20230133671A1/en active Pending
- 2021-02-19 CA CA3168069A patent/CA3168069A1/en active Pending
- 2021-02-19 AU AU2021224855A patent/AU2021224855A1/en active Pending
- 2021-02-19 IL IL295654A patent/IL295654A/en unknown
- 2021-02-19 CN CN202511995231.5A patent/CN121695288A/zh active Pending
- 2021-02-19 MX MX2022010171A patent/MX2022010171A/es unknown
- 2021-02-19 EP EP21757967.1A patent/EP4107157A4/en active Pending
- 2021-02-19 CN CN202180028429.XA patent/CN115380033B/zh active Active
- 2021-02-19 JP JP2022549325A patent/JP2023514280A/ja active Pending
- 2021-02-19 KR KR1020227032446A patent/KR20220143116A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4107157A4 (en) | 2024-03-13 |
| MX2022010171A (es) | 2022-12-06 |
| CA3168069A1 (en) | 2021-08-26 |
| WO2021168313A1 (en) | 2021-08-26 |
| KR20220143116A (ko) | 2022-10-24 |
| EP4107157A1 (en) | 2022-12-28 |
| CN115380033B (zh) | 2026-01-09 |
| AU2021224855A1 (en) | 2022-09-08 |
| CN121695288A (zh) | 2026-03-20 |
| CN115380033A (zh) | 2022-11-22 |
| US20230133671A1 (en) | 2023-05-04 |
| IL295654A (en) | 2022-10-01 |
| JP2023514280A (ja) | 2023-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016573A2 (pt) | Inibidores de setd2 e métodos e usos relacionados, incluindo terapias de combinação | |
| Melekoglu et al. | Beneficial effects of curcumin and capsaicin on cyclophosphamide-induced premature ovarian failure in a rat model | |
| Sarkar et al. | Impaired autophagy flux is associated with neuronal cell death after traumatic brain injury | |
| Seed et al. | Osteoarthritis: a review of treatment options. | |
| El Hajjaji et al. | Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. | |
| Wang et al. | Diosgenin glucoside provides neuroprotection by regulating microglial M1 polarization | |
| Hochberg | New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BRPI0408902A (pt) | composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca | |
| Vijayvargiya et al. | Systematic review with meta‐analysis: efficacy and safety of treatments for opioid‐induced constipation | |
| BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
| Larussa et al. | Downregulation of Interleukin‐(IL‐) 17 Through Enhanced Indoleamine 2, 3‐Dioxygenase (IDO) Induction by Curcumin: A Potential Mechanism of Tolerance Towards Helicobacter pylori | |
| BR112021016296A2 (pt) | Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele | |
| Agnieszka et al. | Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats | |
| Waldeck et al. | Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH‐MYCN neuroblastoma mouse model | |
| BR112017016087A2 (pt) | formulações para coxim articular adiposo e métodos de uso das mesmas | |
| Jordan et al. | Minimally invasive treatment of P eyronie's disease: evidence‐based progress | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| Hummig et al. | Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain. | |
| Lee et al. | Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation | |
| Castino et al. | Persistent histone modifications at the BDNF and Cdk‐5 promoters following extinction of nicotine‐seeking in rats | |
| Folkvord et al. | Radiosensitization by SAHA in experimental colorectal carcinoma models—in vivo effects and relevance of histone acetylation status | |
| BR112023026992A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer | |
| Langworthy et al. | Conservative treatment modalities and outcomes for osteoarthritis: the concomitant pyramid of treatment | |
| BRPI0411665A (pt) | uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina |